Cerevel Therapeutics’ Parkinson’s disease drug meets main goal in late-stage study

By Thomson Reuters Apr 18, 2024 | 5:44 AM

(Reuters) -Cerevel Therapeutics said on Thursday its Parkinson’s disease drug met the main goal of a late-stage trial.

The trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson’s disease.

The results showed that patients using these two drugs had a statistically significant increase in the time in which they had good control over symptoms — such as uncontrolled, involuntary muscle movement — than patients given levadopa and a placebo.

(Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Savio D’Souza)